SEC Form 4 · accession 0001209191-15-028053

Adamas Pharmaceuticals Inc · ADMS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Mar 17, 2015

Accepted (ET)

Mar 19, 2015 · 8:08 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001328143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F2	Mar 17, 2015	S	4,523	$18.00	D	506,805	I	MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF
Common Stock^F3,F2	Mar 18, 2015	S	7,200	$18.0407	D	499,605	I	MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF
Common Stock^F4	holding	—	—		—	3,772,686	I	MDV VII LP, nom for MDV VII LP, MDV VII Leaders' Fund LP, MDV ENF VII (A) LP, and MDV ENF VII (B) LP
Common Stock^F4	holding	—	—		—	265,150	I	MDV VII, L.P.
Common Stock^F4	holding	—	—		—	6,043	I	MDV ENF VII (A), L.P.
Common Stock^F4	holding	—	—		—	3,146	I	MDV ENF VII (B), L.P.
Common Stock^F4	holding	—	—		—	25,661	I	MDV VII Leaders' Fund, L.P.

No Table II lines on this filing.

F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by MDV IX on December 15, 2014.
F2William Ericson is a Managing Member of Ninth MDV Partners, L.L.C., the general partner of MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P. William Ericson may be deemed to share voting and dispositive power over the shares held by MDV IX, L.P., as nominee for MDV IX, L.P., and MDV ENF IX, L.P.
F3Price reflected is the weighted-average sale price for shares sold. The range of the sale prices for the transaction was $18.00 and $18.0900 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer, or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4Seventh MDV Partners, L.L.C. is the general partner of MDV VII, L.P., as nominee for MDV VII, L.P., MDV VII Leaders' Fund, L.P., MDV ENF VII(A), L.P, and MDV ENF(B), L.P. and has sole voting and investment power over the shares. William Ericson, a general partner with Mohr Davidow Ventures, may be deemed to indirectly beneficially own the shares affiliated with Mohr Davidow Ventures.